Expensify (EXFY) Q3 2026 10-Q: $52M of $27 Stock Comp Behind a $1.45 Stock
Listen to this report
The Hook
Expensify $EXFY lost $3.3 million in the third quarter, and $6.4 million of stock-based compensation expense sat inside that loss. Add it back and the quarter's pre-tax result was a profit of about $4.1 million, against the $2.3 million pre-tax loss reported in the 10-Q. Most of that cost is restricted stock units: equity-classified RSUs accounted for $4.98 million of the quarter's $6.67 million of stock compensation cost, before the small part capitalized as software. The 2.52 million RSUs still unvested at September 30 carry an average grant-date value of $27.23 a share. Stockanalysis.com shows the stock closed at $1.45 on November 20.
That expense has years left to run. At September 30, Expensify still had $52.4 million of RSU expense to book over the next 2.86 years. At the $1.45 close of November 20 reported by stockanalysis.com, the 2.52 million unvested units are worth about $3.7 million. The stock comp explains the GAAP loss; it does not explain the rest of the quarter. Subscription fees fell 6.5%, and gross margin before stock comp fell to 52.4% from 57.1%, for reasons that have nothing to do with equity grants. And $10.5 million of buybacks this year cut the share count by only 0.7%.
Company Snapshot
Expensify sells expense-management software, mostly to small and medium-sized businesses, along with the Expensify Card (issued by The Bancorp Bank on the Visa network) and a travel booking product. It reports as one segment. This brief reads the 10-Q for the quarter ended September 30, 2026, filed November 5, 2026, with the FY2025 10-K for trailing figures, the November 5 8-K earnings release, and the insider filings made since the call. Average paid members were 630,000, down from 642,000 a year earlier.
The Financial Story
The top line is still shrinking, and the card is not offsetting it. Revenue fell 6% to $33.0 million. Subscription fees, the core of the business, fell 6.5% to $30.0 million. The card story looks better than it is: interchange rose 7.7% to $5.8 million, but cashback paid back to card customers is booked as contra-revenue and rose 16% to $3.0 million. Net of cashback, the card brought in $2.86 million against $2.86 million a year ago. It was flat.
| Q3 (three months to Sep 30) | 2026 | 2025 | Change |
|---|---|---|---|
| Revenue, net | $33.02M | $35.07M | -5.8% |
| Subscription fees | $30.03M | $32.11M | -6.5% |
| Interchange less cashback | $2.86M | $2.86M | 0.3% |
| Gross margin | 45.2% | 49.6% | -4.4 pts |
| Gross margin before stock comp | 52.4% | 57.1% | -4.7 pts |
| Stock-comp expense | $6.45M | $6.66M | -3.2% |
| Net loss | $(3.34)M | $(2.32)M | wider |
Gross margin fell for a real reason, not an accounting one. Cost of revenue rose 2% to $18.1 million while revenue fell. The MD&A puts it down to more spending on software licenses and subscriptions and higher amortization of capitalized software. Stock comp in cost of revenue actually fell, to $2.37 million from $2.63 million, so the margin is lower even before stock comp: 52.4%, against 57.1% a year ago. That is the number to watch in the next quarter.
Most of the stock comp is RSUs valued far above today's price. Of the $20.6 million of stock comp recognized in the first nine months, $15.3 million came from equity-classified RSUs. The weighted-average grant-date value on the 2.52 million that remain unvested is $27.23, down from $30.30 at December 31, 2025. That pool is mixed: it includes 371,286 Class A units granted this year at an average of $1.14, and the filing does not say when the rest were granted. Whatever their date, the grants are expensed at their grant-date value, not at the current price. Nine-month stock-comp expense of $19.6 million was more than double the $9.5 million net loss and well above the $12.6 million of operating cash flow. Over the trailing twelve months, stock comp was $24.6 million against $13.5 million of free cash flow on our definition (operating cash flow less capital spending and capitalized software, from the FY2025 10-K and this 10-Q).
The same grants help explain the tax bill. Expensify charged $2.7 million of income tax in the first nine months on a $6.8 million pre-tax loss, an effective rate of negative 39.4%. The filing says why: "primarily due to non-deductible stock-based compensation." When an RSU vests below its grant-date value, the tax deduction follows the vesting value, so much of the book expense never becomes a deduction. This is not just an accrual. Income taxes paid, net of refunds, were also $2.7 million, so charged and paid line up. Paid tax was down from $4.9 million a year ago; the filing notes that since 2025 the company deducts domestic R&D costs in the year they are incurred instead of capitalizing them.
The balance sheet is clean and the cash is real. Cash and equivalents were $63.7 million at September 30, with no borrowings. The old loan agreement has been terminated, and a $7.5 million standby letter of credit is undrawn. Accrued liabilities fell by $10.5 million this year, mostly because the $9.5 million IPO class-action settlement went into escrow. Insurers paid $6.9 million of it and Expensify paid $2.6 million, which is inside the nine-month operating cash flow. Without that one-off, cash generation would have looked better than the $9.3 million of nine-month free cash flow on our definition. The company reports $12.2 million, because its own measure also excludes changes in settlement assets and liabilities.
Buybacks are mostly running to stand still. The quarter-by-quarter record, from the equity statement:
| 2026 | Shares repurchased | Cost | Shares issued, net | Share count at end |
|---|---|---|---|---|
| Q1-Q2 | 6,765,040 | $9.23M | 5,601,205 | 91,897,067 |
| Q3 | 722,121 | $1.27M | 1,205,483 | 92,380,429 |
| Nine months | 7,487,161 | $10.49M | 6,806,688 | down 680,473 (0.7%) |
Most of the buyback was the June Dutch-auction tender. It was offered at up to $25 million, but only 6,053,023 shares came in at $1.20, and the company says the total cost was $8.0 million, of which $0.7 million was fees. The issuance is mostly the employee Matching Plan: 5,215,027 shares this year, of which employees paid $4.2 million for most and the company granted 1,412,921 as a match. In Q3 the share count went up by 483,362 despite the buyback. $38.6 million is left on the 2025 authorization. The plan reserve also refills by up to 6% of the share count every January through 2031, and the board granted 5.58 million new options to executives and directors in June at an average exercise price of $1.75.
An insider sold into the slide. Form 4 filings show that Steven J. McLaughlin, a 10% owner, sold 1,384,569 Class A shares between November 9 and November 18 at weighted-average prices from $1.62 to $1.85, about $2.4 million in total. That is nearly twice the 722,121 shares the company bought back in all of Q3. The filings do not mark the sales as made under a 10b5-1 plan. Separately, a 13G/A filed November 10 shows Octopus Head, Inc. holding 5.4 million Class A shares, or 6.8% of the class.
The 10-Q does not mention the story the release leads with. Expensify's November 5 8-K earnings release (EX-99.1) opens with "Revenue from New Expensify increased 30% from Q2, and is up 212% y/y." The 10-Q never uses the words "New Expensify" and gives no revenue figure for it, so the 212% cannot be tied to a dollar amount in the filed statements. The FY2025 10-K mentions New Expensify only in its risk factors.
Valuation: what it's worth as a normal business
Where it trades. At $1.45 (November 20 close, per stockanalysis.com), the 92,393,539 shares on the 10-Q cover page are worth $134.0 million. Take off $63.7 million of cash and the enterprise value is about $70.2 million. That is 0.52 times trailing revenue of $136.1 million and about 5.2 times trailing free cash flow of $13.5 million. Stockanalysis.com, read on November 21, lists three analysts at an average Hold, with a $2.83 target. The November 5 8-K release raised FY2026 free-cash-flow guidance by $1.5 million, to $13.5 million to $15.5 million. Earnings Whispers (November 5) called that raise "backward-looking".
Scenario DCF. These use the house 9% discount rate and five years of explicit free cash flow, added to $63.7 million of net cash and divided by 92.39 million shares. The bear case drops terminal growth to 0%, because a business whose revenue keeps shrinking should not get the 3% default.
| Scenario | Starting FCF | FCF growth, years 1-5 | Terminal growth | Implied value per share |
|---|---|---|---|---|
| Bear: Classic decline wins | $8M | -10% a year | 0% | $1.38 |
| Base: flat, decline offset | $12M | 0% | 3% | $2.64 |
| Bull: New Expensify crossover | $12M | 10% a year | 3% | $3.42 |
The base case starts below the trailing $13.5 million on purpose, to allow for continued revenue decline and for the cash a buyback has to spend to keep the share count flat. As a re-rating check, applying 0.5, 1.0 and 1.5 times trailing sales gives $1.43, $2.16 and $2.90 a share including cash. At the $1.45 stockanalysis.com close of November 20, the enterprise value is matched by flat free cash flow of about $6.3 million a year forever with no growth, under half the trailing figure. The price sits at the bear case. This is implied value under stated assumptions, not a price target and not investment advice.
Risks
The biggest risk is in the filing: subscription revenue is down 6.5% and paid members are down 2%, and the gross margin before stock comp fell almost five points in a year. If New Expensify cannot be seen in the reported numbers, the bear case is the base case. Dilution is structural: the 6% evergreen refill, 8.67 million options outstanding after the June grant, and a Matching Plan that issued more shares this year than the open-market buyback retired. There is a dual-class structure, with LT10 and LT50 shares carrying 10 and 50 votes each, and four shareholder derivative suits are still pending, which the company expects insurance to cover. The stock fell below $1 earlier this year and got a Nasdaq deficiency letter on April 17; it regained compliance on May 28, and the 10-Q warns this could happen again.
The Bottom Line
The GAAP loss is real, but most of it is stock comp: add back $6.4 million and the quarter was a pre-tax profit of about $4.1 million, with $63.7 million of cash and no debt. That expense will keep running for about three more years, $52.4 million of it on RSUs whose average grant-date value is $27.23, and it helps explain why Expensify charged and paid $2.7 million of income tax this year on a pre-tax loss. What the stock comp does not explain is the business underneath: subscription fees down 6.5%, paid members down 2%, and gross margin before stock comp down 4.7 points. The share count is the other cost. $10.5 million of buybacks bought a 0.7% reduction, and a 10% owner sold more in eight trading days after the call than the company bought back all quarter. Watch three things next quarter: subscription fees, gross margin before stock comp, and whether the share count falls at all.
Nobody wrote this by hand from a model. Every number about Expensify's own results came out of its SEC filings: the 10-Q, the FY2025 10-K, the November 5 8-K release, and the Forms 4 and 13G/A filed since. The same pipeline reads any of the companies that file with the SEC, and a private company reporting in the same format is the same job.
Figures from Expensify, Inc.'s SEC filings (10-Q for the quarter ended September 30, 2026; FY2025 10-K; 8-K earnings release of November 5, 2026; Forms 4 and 13G/A filed November 2026), read through the RoboSystems SEC repository. Market data attributed in the text.
Ask the filing yourself
Every figure in this report came from Expensify, Inc.'s SEC filings in the RoboSystems SEC Shared Repository. Connect it to Claude or ChatGPT and ask your own questions, starting with this one:
How much unrecognized stock-based compensation did Expensify still have on unvested RSUs at September 30, 2026, and what was their average grant-date fair value?